Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial
Filed with ASX · · 2 pages · English
Story so far
Earlier from Biotron
- Response to ASX Appendix 4C Query
- Biotron Compounds Demonstrate Activity Against HBV
- $1.6 Million R&D Tax Incentive Received
- BIT225 Phase 2 HIV-1 Clinical Trial Update
- $1.6 Million R&D Tax Rebate Received
Later from Biotron
- Significant Immunological Outcomes in BIT225 HIV-1 Trial
- $1.07 million R&D Tax Incentive Received
- Biotron Secures $4.7 Million Underwriting Agreement
- Response to ASX aware letter
- Presentation of BIT225-009 HIV-1 Phase 2 data
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron